FlyteHealth achieves significant weight loss results, averaging 15.8% with non-GLP-1s and further improvements with GLP-1s.

In this episode, Gabe Castaneda, Chief Revenue Officer at FlyteHealth, talks about advancements and issues in obesity management, particularly focusing on GLP-1 medications. With 25 years of healthcare experience, Gabe highlights FlyteHealth’s innovative approach combining lifestyle management with clinical medication management. FlyteHealth's patented algorithm delivers personalized care, often utilizing non-GLP-1s to reduce costs and avoid side effects and aiming for sustainable weight loss. He also discusses the company's strategic partnerships and expansion plans, advocates for avoiding GLP-1s, and warns against compound prescriptions.

Tune in to discover how FlyteHealth is revolutionizing obesity management with innovative solutions!

Resources:

Connect with and follow Gabe Castaneda on LinkedIn.

Follow FlyteHealth on LinkedIn and visit their website.